Tarlatamab

monoclonal antibody

Identifier: CI-DRUG-00000764
Entity page: /drug/tarlatamab ↗
Edges: 70

Neighbours: 16 cancers4 genes10 trials3 approvals
Drawn: 33 of 33 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Tarlatamab approved for …APPROVED_FOR5 of 3
→ approved for	Lung Small Cell Carcinomasubtype	supports	FDA ORIG	Lung Small Cell Carcinoma	1	Regulatory	openfda	graph →
→ approved for	Lung Small Cell Carcinomasubtype	supports	EMA indication text

Tarlatamab targets …TARGETS4 of 4
→ targets	CD3D	—	BINDING AGENT	—	1	Curated	chembl	graph →
→ targets	CD3G	—	BINDING AGENT	—	1	Curated	chembl	graph →
→ targets	DLL3	—	BINDING AGENT	—	1	Curated	chembl	graph →
→ targets	CD3E	—	BINDING AGENT	—	1	Curated	chembl	graph →

Tarlatamab targets …TARGETS4 of 4

→ targets

CD3D

—

BINDING AGENT

—

Curated

Tarlatamab investigated for …INVESTIGATED_FOR2 of 2
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Lung Small Cell Carcinomasubtype	unknown	4	Lung Small Cell Carcinoma	1	Curated	chembl	graph →

Tarlatamab investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 26show all (up to 200)
→ investigated in trials for	Lung Small Cell Carcinomasubtype 22 trials (19 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Small Cell Carcinoma	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Neuroendocrine Carcinoma 3 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Neuroendocrine Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Central Nervous System Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Central Nervous System Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Astrocytic Tumor 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Astrocytic Tumor	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Brain Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Brain Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Childhood Central Nervous System Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Childhood Central Nervous System Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Extrapulmonary Neuroendocrine Carcinoma 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Extrapulmonary Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Glioblastoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Glioblastoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Glioma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Glioma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	High-Grade Glioma, NOS 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	High-Grade Glioma, NOS	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Large Cell Neuroendocrine Carcinoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Large Cell Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Bladder Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Cervical Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Cervical Neoplasm	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Prostate Neoplasm 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Prostate Neoplasm	1	Observed	clinicaltrials	graph →

Tarlatamab studied in …STUDIED_INderived10 of 35show all (up to 200)
→ studied in	NCT07037758Phase 1 · recruiting A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) · 35 trials list this drug (30 active)	—	—	Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06814496Phase 1/Phase 2 · recruiting Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors · 35 trials list this drug (30 active)	—	—	Melanoma,Glioblastoma,Lung Non-Small Cell Carcinoma+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT07203053Phase 2 · recruiting A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 · 35 trials list this drug (30 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT07061080Phase 2 · terminated Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab · 35 trials list this drug (30 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT06816394Phase 2 · recruiting Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS) · 35 trials list this drug (30 active)	—	—	Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07778316Phase 3 · recruiting Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) · 35 trials list this drug (30 active)	—	—	Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07243470Phase 1/Phase 2 · recruiting Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors · 35 trials list this drug (30 active)	—	—	Adult Central Nervous System Neoplasm,Childhood Central Nervous System Neoplasm,Glioma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05361395Phase 1 · active not recruiting First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) · 35 trials list this drug (30 active)	—	—	Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07016230Phase 2 · recruiting Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB) · 35 trials list this drug (30 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT07005128Phase 3 · active not recruiting A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) · 35 trials list this drug (30 active)	—	—	Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths